OncoMatch/Clinical Trials/NCT06834282
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Is NCT06834282 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CER-1236 and Cyclophosphamide for aml.
Treatment: CER-1236 · Cyclophosphamide · Fludarabine · Mesna — This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: permanently integrated, genetically modified cell product
Prior therapy with a permanently integrated, genetically modified cell product
Lab requirements
Blood counts
absolute lymphocyte count >0.3 x 10^9/l prior to apheresis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Davis Comprehensive Cancer Center · Sacramento, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Sarah Cannon Research Insitute · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify